![Carole Monterrat](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Carole Monterrat
Keine laufenden Positionen mehr
Profil
Carole Monterrat worked as the Chief Financial Officer at Sopartec SA from 2014 to 2018 and as the Vice President-Resources at PROMETHERA Biosciences SA from 2009 to 2014.
She holds a doctorate from Université de Bordeaux and an MBA from Université Catholique de Louvain, which she received in 2008.
Ehemalige bekannte Positionen von Carole Monterrat
Unternehmen | Position | Ende |
---|---|---|
Sopartec SA
![]() Sopartec SA Investment ManagersFinance Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium. | Finanzdirektor/CFO | 01.09.2018 |
PROMETHERA Biosciences SA
![]() PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Corporate Officer/Principal | 01.03.2014 |
Ausbildung von Carole Monterrat
Université de Bordeaux | Doctorate Degree |
Université Catholique de Louvain | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
PROMETHERA Biosciences SA
![]() PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium. | Health Technology |
Sopartec SA
![]() Sopartec SA Investment ManagersFinance Sopartec SA is the investment and technology valorization arm of Université Catholique de Louvain (UCL) and was founded in 1942. Sopartec SA is headquartered in Louvain-la-Neuve, Belgium. | Finance |